Genine Winslow, MSc

Title: CEO & President

Organization: Chameleon Biosciences

Bio: Genine Winslow, MSc., founded Chameleon Biosciences in 2017 to provide next-generation gene therapies to treat more patients. Prior to founding Chameleon, Ms. Winslow was in leadership roles relating to CMC and analytic development at several gene therapy start-ups including BlueBird Bio, and Audentes Therapeutics. She led and managed the BioMarin analytical development and testing for their first Hemophilia A clinical trial. Ms. Winslow studied immunology with James P. Allison at UC Berkeley.

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

Deanna Tucker

Senior Medical Science Liaison

Sarepta Therapeutics

Genine Winslow, MSc

CEO & President

Chameleon Biosciences